FLGT · Fulgent Genetics, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 30, 2026TL;DR. Fulgent reported Q2 revenue of $85.4 million (up 4% YoY, 20% sequential) but cut full-year 2026 revenue guidance to $330–$340 million from $350 million due to billing-system transition delays and lost revenue from a top customer moving testing in-house, while advancing FID-007 Phase 2/3 plans and FID-022 dose escalation.
- + Revenue grew 20% sequentially to $85.4 million in Q2 2026.
- + FID-022 Phase 1 dose escalation advanced with fourth dose level completed.
- + Bako and StrataDx integration added $16.9 million in Q2 revenue and roughly doubled the anatomic pathology sales team to ~40.
- + Cash position remains strong at $551.5 million with an additional ~$106.1 million federal tax refund anticipated.
- − Full-year 2026 revenue guidance cut to $330–$340 million from prior $350 million on billing transition and customer loss.
- − Revenue cycle management system transition is suppressing collection rates and delaying billing across the lab business.
- − Largest customer is in-housing testing, with revenue from that customer down $4.6 million sequentially and expected to keep declining.
- − GAAP gross margin fell sharply to 30.1% from 42.1% YoY on lower collections.
- − Full-year non-GAAP EPS loss guidance widened to $(2.22)–$(2.35) per share.
- − Q2 GAAP loss widened to $29.5 million, including a $2.2 million customer-related impairment charge.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FLGT
this stock
Fulgent Genetics, Inc.
|
$610.84M | -16.2% | +2.5% | — | 8.4% |
|
TMO
Thermo Fisher Scientific Inc.
|
$249.58B | +16.5% | +14.5% | 36.3 | 1.4% |
|
DHR
Danaher Corp /De/
|
$155.42B | -3.2% | +8.5% | 39.2 | 1.2% |
|
NTRA
Natera, Inc.
|
$59.47B | +80.4% | -2.8% | — | 3.3% |
|
A
Agilent Technologies, Inc.
|
$48.90B | +26.6% | +6.4% | 34.2 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FLGT | +3.5% | +12.4% | +46.6% | +13.7% | -16.2% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +4.2% | +12.3% | +34.4% | +14.3% | -28.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.